Hence, the TRPML1–TFEB pathway may represent a potential therapeutic target by which preemptive modulation of oxidative stress may alleviate symptoms in patients with lysosomal storage diseases and neurodegenerative diseases characterized by excess ROS. This evidence concerns the gene TFEB and neurodegenerative disease.